MIV-160

Therapy Area
NNRTI for the use as a vaginal formulation preventing HIV transmission and for the treatment of patients with HIV.

Competitive Edge
Fast and efficient inactivation of HIV and reduced risk of resistance developing than current NNRTI.

Licensee
Wuhan Humanwell Hi-Tech Industry Co. Ltd. is developing MIV-160 for many different application areas.

Last Modified: 05/09/2008